Buying pressure lifts UiPath stock higher in today's trading

Traders Union
All News
Financial News
Uipath surges 2.72% to $11.89 today

Highlights

UiPath grew revenue nearly 13% year-over-year in FY26 with gross margins above 80%, beating consensus in Q4.
Partnership with Deloitte deepened through an AI-driven ERP solution, while a new $500 million share buyback launched after exhausting a prior $1 billion authorization.
Despite short-term stabilization and session highs, PATH trades below major trend lines with strong selling pressure and is likely to remain sideways between $11.00 and $11.99, with downside risk if support at $11.41 fails.

Revenue growth and buyback expansion as sentiment lifts post-earnings

UiPath recently reported financial results for fiscal year 2026, delivering nearly 13% year-over-year revenue growth and gross margins exceeding 80%. The company surpassed consensus estimates in the fourth quarter and highlighted continued stabilization in net new annual recurring revenue. UiPath also expanded its partnership with Deloitte to launch an AI-powered Agentic ERP solution and started a new $500 million share buyback program after concluding a previous $1 billion buyback.

Anton Kharitonov, expert at Traders Union, notes that UiPath trades below key medium- and long-term averages, showing clear structural weakness. He sees recent financial results as only mildly supportive due to ongoing margin pressure and a lack of sustainable trend in net new revenue. Kharitonov remains critical of the current momentum, pointing to indecision in oscillators and a fragile technical backdrop. He highlights that the low probability of upside and potential for a breakdown below $11.41 pose real risks for traders. "Near-term strength appears fragile — without a decisive move above $13.01, downside scenarios dominate my outlook."

Viktoras Karapetjanc, expert at Traders Union, highlights UiPath’s double-digit revenue growth and robust gross margins as a solid foundation for further expansion. He sees the new $500 million buyback and deepening Deloitte partnership as important signals of management’s confidence and long-term growth potential. Karapetjanc believes short-term volatility is secondary to the company’s strong execution and healthy fundamentals. "With resilient financials and positive news momentum, the market offers multiple opportunities for patient, forward-looking investors."

Jainam Mehta, market strategist, observes a mixed technical landscape with a short-term push but ongoing medium-term vulnerability. He believes macro-driven sentiment and lagging momentum indicators may create tactical setups for contrarian traders. Mehta notes that a close watch on the $13.01 resistance could reveal potential for a breakout if momentum shifts. "I see divergence in price action and sentiment here — if upside flows emerge, there’s room for a tactical move above resistance."

Momentum divergence as buyers test session highs amid trend weakness

In terms of momentum, the daily MACD shows strong selling pressure, while ADX suggests a weak trend. RSI is just below neutral, and there is a mix of overbought and oversold signals across Stoch RSI and CCI, highlighting overall indecision. BBP points to buyers leading intraday momentum, and the AO is neutral despite today's price rising by 2.72%. There was no gap between the previous close and today's open, and the price is currently positioned near the upper end of today’s range, with moderate volatility. After the open, the tone has shifted towards persistent strength near session highs; however, daily indicators show a clear divergence between short-term buying interest and broader trend weakness.

Earlier, analysts noted that UiPath was exhibiting short-term bullish momentum while facing continued longer-term headwinds, with conflicting technical signals and limited near-term upside. The current setup reinforces this view, and traders should monitor the $11.41 support level for possible downside risk if volatility increases.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.